TYRA-300 is under clinical development by Tyra Biosciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TYRA-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TYRA-300 is under development for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract and solid tumors. The drug candidate acts by targeting fibroblast growth factor (FGF) receptor 3. It is being developed based on SNAP platform. It is administered by oral route.
Tyra Biosciences overview
Tyra Biosciences (Tyra) is a precision oncology company. It design and develop cancer drugs. It is investigating Tyra-300, an FGFR3 (fibroblast growth factor receptor 3) inhibitor targeting bladder and solid tumors. The company is also evaluating FGFR2 small molecule inhibitor for the treatment of bile duct and solid tumors; FGFR3 (ACH) program against achondroplasia; an RET-specific inhibitor for lung and thyroid cancer; and FGFR4-specific inhibitor liver and solid tumors. It utilizes SNAP, a proprietary in-house discovery engine to discover and develop molecular structures for cancer. Tyra is headquartered in Carlsbad, California, the US.
For a complete picture of TYRA-300’s drug-specific PTSR and LoA scores, buy the report here.